NASDAQ · CMPS
Healthcare · Medical - Care Facilities
$13.27
Down-$0.02 (-0.15%)
Updated Sep 8, 2026, 8:27 AM
SID Score
5.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CMPS closed at $13.27 after 20 trading sessions, up 0.68% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $13.17 | $13.3837 | $13.05 | $13.27 | 794.91K |
| Sep 3, 2026 | $13.03 | $13.30 | $12.725 | $13.29 | 1.83M |
| Sep 2, 2026 | $13.31 | $13.60 | $13.00 | $13.23 | 1.93M |
| Sep 1, 2026 | $13.41 | $13.4925 | $13.12 | $13.24 | 1.89M |
| Aug 31, 2026 | $13.795 | $13.9394 | $13.4332 | $13.51 | 1.78M |
| Aug 28, 2026 | $14.595 | $14.71 | $13.6881 | $13.73 | 2.65M |
| Aug 27, 2026 | $14.63 | $14.93 | $14.40 | $14.64 | 1.66M |
| Aug 26, 2026 | $14.79 | $15.01 | $14.565 | $14.61 | 1.74M |
| Aug 25, 2026 | $14.40 | $14.92 | $14.30 | $14.88 | 2.28M |
| Aug 24, 2026 | $13.405 | $14.32 | $13.08 | $14.20 | 2.78M |
| Aug 21, 2026 | $13.82 | $14.02 | $13.30 | $13.33 | 2.08M |
| Aug 20, 2026 | $14.00 | $14.20 | $13.65 | $13.82 | 2.04M |
| Aug 19, 2026 | $13.93 | $14.17 | $13.6801 | $14.01 | 2.84M |
| Aug 18, 2026 | $13.55 | $14.00 | $13.22 | $13.90 | 3.27M |
| Aug 17, 2026 | $13.39 | $13.80 | $13.2697 | $13.72 | 1.8M |
| Aug 14, 2026 | $13.26 | $13.48 | $13.06 | $13.45 | 1.36M |
| Aug 13, 2026 | $14.20 | $14.20 | $13.28 | $13.29 | 2.39M |
| Aug 12, 2026 | $13.75 | $14.59 | $13.65 | $14.22 | 4.09M |
| Aug 11, 2026 | $13.48 | $13.69 | $13.20 | $13.38 | 2.19M |
| Aug 10, 2026 | $13.60 | $13.62 | $13.07 | $13.18 | 1.82M |
The latest Smart Investors Daily articles mentioning CMPS.
CMPS research
Company profile and research snapshot.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
| Aug 6, 2026 | Morgan Stanley | Overweight | — |
| Aug 6, 2026 | B. Riley Securities | Buy | — |
| Jul 27, 2026 | Wells Fargo | Equal-Weight | — |
No generated briefing is available yet.
SeekingAlpha · Aug 25, 2026
Compass Pathways plc is rated Strong Buy with a $25â$30 fair value, reflecting a significant upside to current levels. Read more on CMPS stock here.
SeekingAlpha · Aug 25, 2026
Compass Pathways stays a Buy, but Eli Lillyâs AtaiBeckley deal raises competition and funding risks. Click to get key timelines, cash runway & strategy.
Yahoo · Aug 24, 2026
The most closely watched next step for Compass is the completion of its application to the U.S. Food and Drug Administration for COMP360, its synthetic psilocybin treatment aimed at people with depression that has not responded to other options.
SeekingAlpha · Aug 21, 2026
Helus Pharma's psychedelic pipeline targets MDD & GAD with HLP003 psilocin and HLP004 DMT; Phase III could rerate shares. Click to read my analysis.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CMPS.
